this is an example in which therapy with individual enantiomers might be justified. Kroemer and his colleagues32 have previously reported that R-propafenone inhibits the CYP2D6-mediated metabolism of S-propafenone in vitro. In the present study, they asked whether such an enantiomer/enantiomer interaction occurs in human subjects. In the study reported in this issue of Circulation,7 they found that, indeed, there is a striking interaction of this type. In seven subjects, all known to have the EM phenotype, plasma concentrations of the (3-blocking enantiomer S-propafenone were in fact higher during treatment with 150 mg every 6 hours of the racemate (which contains only 75 mg of S-propafenone) than they were during treatment with 150 mg every 6 hours of S-propafenone alone. Importantly, there was a reasonable correspondence between elevated plasma concentrations of S-propafenone and indexes of (-blockade. They excluded a number of possible potential confounding factors, such as variable absorption or racemization in vivo (a phenomenon whereby administration of a pure enantiomer results in formation of the opposite enantiomer33). Thus, it seems likely that, as in vitro, R-propafenone inhibits the CYP2D6-mediated metabolism of S-propafenone.
The findings have somewhat limited implications for whether or not enantiomer-specific therapy should be considered in the case of propafenone. The data indicate that to achieve (-blockade and sodium channel blockade during enantiomer-specific therapy with S-propafenone, much higher dosages than previously anticipated would be required. One could argue that a molecule with multiple actions might be undesirable, so if enantiomer-specific therapy is preferred, it should be with the non-3-blocking R-enantiomer; in fact, this is the rationale underlying current efforts to develop d-sotalol,m the very weak (-blocking enantiomer of racemic sotalol, which nevertheless preserves the racemate's other electrophysiological actions. In either case, should (-blockade be desired, a (-blocker could be administered separately.
The study is an important addition to the growing body of knowledge that will be used to set standards about enantiomer-specific therapy. Although the concept does have attractions, there are practical difficulties in its implementation. These include potential difficulties in synthesizing pure enantiomers as well as the possibility of racemization in vivo. The present study also demonstrates that the effects of therapy with a racemate may not necessarily be determined by simply summing the effects of the individual enantiomers. Thus, programs to develop enantiomer-specific therapy from existing racemates must take cognizance of the phenomenon reported here by Kroemer et al.7 It is also not far-fetched to speculate that enantiomer/enantiomer interactions may occur not only at drug-metabolizing enzymes but also at other molecules, such as enzymes, receptors, or ion channels, which drugs target. Indeed, an analogous interaction between a parent drug and its metabolite has been described for lidocaine block of the sodium channel. 35 In addition, other mechanisms for enantiomer/enantiomer interactions are possible3: for example, the clearance of racemic propranolol is lower than that of d-propranolol, not because of a competitive metabolic interaction but because (-blockade (due to l-propranolol) decreases liver blood flow, which in turn decreases the clearance of the racemate. 36 A generic problem that the discipline of clinical pharmacology addresses is the definition of the sources of individual variability in response to drug therapy in human beings. Thus, perhaps the most important lesson of the study reported by Kroemer and colleagues7 is that well-conducted in vitro experimentation can be used both to understand mechanisms of variable responses to drug therapy and to suggest experiments to validate those mechanisms in human beings. With the cloning of individual molecules responsible for drug actions, such as specific P450s, ion channels, receptors, and other proteins, will come the development of new tools that we hope will allow us to make the "idiosyncratic" drug reaction a relic of our ignorant past.
